These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36460469)

  • 1. Prevalence of Spinal Muscular Atrophy in the Era of Disease-Modifying Therapies: An Italian Nationwide Survey.
    Coratti G; Ricci M; Capasso A; D'amico A; Sansone V; Bruno C; Messina S; Ricci F; Mongini T; Coccia M; Siciliano G; Pegoraro E; Turri M; Filosto M; Comi G; Masson R; Maggi L; Bruno I; D'Angelo MG; Trabacca A; Vacchiano V; Donati M; Simone I; Ruggiero L; Varone A; Verriello L; Berardinelli A; Agosto C; Pini A; Maioli MA; Passamano L; Brighina F; Carboni N; Garibaldi M; Zuccarino R; Gagliardi D; Siliquini S; Previtali S; Taruscio D; Boccia S; Pera MC; Pane M; Mercuri E;
    Neurology; 2023 Mar; 100(11):522-528. PubMed ID: 36460469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the SMN2 gene copy number and clinical characteristics of patients with spinal muscular atrophy with homozygous deletion of exon 7 of the SMN1 gene.
    Zarkov M; Stojadinović A; Sekulić S; Barjaktarović I; Perić S; Keković G; Drasković B; Stević Z
    Vojnosanit Pregl; 2015 Oct; 72(10):859-63. PubMed ID: 26665550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic and expression studies of SMN2 gene in Russian patients with spinal muscular atrophy type II and III.
    Zheleznyakova GY; Kiselev AV; Vakharlovsky VG; Rask-Andersen M; Chavan R; Egorova AA; Schiöth HB; Baranov VS
    BMC Med Genet; 2011 Jul; 12():96. PubMed ID: 21762474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Quantitative analysis of the genes determining spinal muscular atrophy].
    Nagymihály M; Herczegfalvi A; Tímár L; Karcagi V
    Ideggyogy Sz; 2009 Nov; 62(11-12):390-7. PubMed ID: 20025129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of SMN2 copy number and NAIP deletion predicts disease severity in spinal muscular atrophy.
    Watihayati MS; Fatemeh H; Marini M; Atif AB; Zahiruddin WM; Sasongko TH; Tang TH; Zabidi-Hussin ZA; Nishio H; Zilfalil BA
    Brain Dev; 2009 Jan; 31(1):42-5. PubMed ID: 18842367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intragenic mutations in SMN1 may contribute more significantly to clinical severity than SMN2 copy numbers in some spinal muscular atrophy (SMA) patients.
    Yamamoto T; Sato H; Lai PS; Nurputra DK; Harahap NI; Morikawa S; Nishimura N; Kurashige T; Ohshita T; Nakajima H; Yamada H; Nishida Y; Toda S; Takanashi J; Takeuchi A; Tohyama Y; Kubo Y; Saito K; Takeshima Y; Matsuo M; Nishio H
    Brain Dev; 2014 Nov; 36(10):914-20. PubMed ID: 24359787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis.
    Abiusi E; Vaisfeld A; Fiori S; Novelli A; Spartano S; Faggiano MV; Giovanniello T; Angeloni A; Vento G; Santoloci R; Gigli F; D'Amico A; Costa S; Porzi A; Panella M; Ticci C; Daniotti M; Sacchini M; Boschi I; Dani C; Agostiniani R; Bertini E; Lanzone A; Lamarca G; Genuardi M; Pane M; Donati MA; Mercuri E; Tiziano FD;
    J Med Genet; 2023 Jul; 60(7):697-705. PubMed ID: 36414255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years.
    Vill K; Schwartz O; Blaschek A; Gläser D; Nennstiel U; Wirth B; Burggraf S; Röschinger W; Becker M; Czibere L; Durner J; Eggermann K; Olgemöller B; Harms E; Schara U; Kölbel H; Müller-Felber W
    Orphanet J Rare Dis; 2021 Mar; 16(1):153. PubMed ID: 33789695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotype-phenotype correlation of SMN locus genes in spinal muscular atrophy children from Argentina.
    Medrano S; Monges S; Gravina LP; Alías L; Mozzoni J; Aráoz HV; Bernal S; Moresco A; Chertkoff L; Tizzano E
    Eur J Paediatr Neurol; 2016 Nov; 20(6):910-917. PubMed ID: 27510309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of spinal muscular atrophies in a sample of the Italian population.
    Mostacciuolo ML; Danieli GA; Trevisan C; Müller E; Angelini C
    Neuroepidemiology; 1992; 11(1):34-8. PubMed ID: 1608493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal muscular atrophy: recent advances and future prospects.
    Nicole S; Diaz CC; Frugier T; Melki J
    Muscle Nerve; 2002 Jul; 26(1):4-13. PubMed ID: 12115944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [SMA: from gene discovery to gene therapy].
    Barkats M
    Med Sci (Paris); 2020 Feb; 36(2):137-140. PubMed ID: 32129749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural history in spinal muscular atrophy Type I in Taiwanese population: A longitudinal study.
    Ou SF; Ho CS; Lee WT; Lin KL; Jones CC; Jong YJ;
    Brain Dev; 2021 Jan; 43(1):127-134. PubMed ID: 32878721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The analysis of the association between the copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein genes and the clinical phenotypes in 40 patients with spinal muscular atrophy: Observational study.
    Zhang Y; He J; Zhang Y; Li L; Tang X; Wang L; Guo J; Jin C; Tighe S; Zhang Y; Zhu Y; Zhu B
    Medicine (Baltimore); 2020 Jan; 99(3):e18809. PubMed ID: 32011487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.
    Feldkötter M; Schwarzer V; Wirth R; Wienker TF; Wirth B
    Am J Hum Genet; 2002 Feb; 70(2):358-68. PubMed ID: 11791208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spinal muscular atrophy - insights and challenges in the treatment era.
    Mercuri E; Pera MC; Scoto M; Finkel R; Muntoni F
    Nat Rev Neurol; 2020 Dec; 16(12):706-715. PubMed ID: 33057172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nusinersen treatment of spinal muscular atrophy - a systematic review.
    Albrechtsen SS; Born AP; Boesen MS
    Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial.
    Strauss KA; Farrar MA; Muntoni F; Saito K; Mendell JR; Servais L; McMillan HJ; Finkel RS; Swoboda KJ; Kwon JM; Zaidman CM; Chiriboga CA; Iannaccone ST; Krueger JM; Parsons JA; Shieh PB; Kavanagh S; Wigderson M; Tauscher-Wisniewski S; McGill BE; Macek TA
    Nat Med; 2022 Jul; 28(7):1390-1397. PubMed ID: 35715567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between SMN2 methylation and disease severity in Chinese children with spinal muscular atrophy.
    Cao YY; Qu YJ; He SX; Li Y; Bai JL; Jin YW; Wang H; Song F
    J Zhejiang Univ Sci B; 2016 Jan; 17(1):76-82. PubMed ID: 26739529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity.
    Harada Y; Sutomo R; Sadewa AH; Akutsu T; Takeshima Y; Wada H; Matsuo M; Nishio H
    J Neurol; 2002 Sep; 249(9):1211-9. PubMed ID: 12242541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.